| Management target | Revenue FY28 |
|---|
| Revenue growth | 37% YoY growth driven by Semaglutide and new MSA contracts. |
|---|---|
| Margins | EBITDA margins at ~27.5%; target expansion to 40% by FY28. |
| Order book | Robust CDMO demand; full capacity utilized despite partner supply issues. |
| Demand visibility | Strong; RFP funnel for biologics is 4x larger than last year. |
| Management confidence | High; reiterating FY28 targets despite temporary supply chain disruptions. |
Growth
Revenue grew 37% YoY to ₹4,490 million, driven by Semaglutide commercial launch and new MSA contracts. EBITDA rose 39% YoY.
Outlook
FY28 guidance reiterated at $400 million organic revenue with 40% EBITDA margins. New cartridge lines doubling capacity.
Risks
Heavy reliance on Dr. Reddy's for supply; temporary site shutdowns for capacity expansion could impact near-term volumes.
Last quarter's promises, checked
Delivered
- New line capacity available Q2 → On track for commercialization (= BEAT)
- India Semaglutide launch end of quarter → Captured 2/3 market share (= BEAT)
- US/Canada Semaglutide approvals → Secured first 3 generic approvals (= BEAT)
Partly delivered
- Steriscience/Brooks merger → Deferred until FY28 targets met (= PARTIAL)
Missed
- FY26 Revenue → INR 14,216M vs prior year (2% decline) (= MISS)
Earnings Call Transcript filed with BSE, NSE: ONESOURCE. Summary written with AI assistance from the document.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,602.60
- Market cap
- ₹18,377 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -378.0×Sector 50.4×
- Promoter holding
- 30.48%+0.00% QoQ
- FII holding
- 19.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Employee Stock Options
Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.
- Value
- ₹0.03 Cr
OneSource Specialty Pharma Management Change
Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.
OneSource Specialty Pharma Other Announcement
OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.